The Advancement of Biomarker-Based Diagnostic Tools for Ovarian, Breast, and Pancreatic Cancer through the Use of Urine as an Analytical Biofluid
Authors:
Open Access
- 1 July 2011
- journal article
- review article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 26 (3) , 141-152
Abstract
Despite considerable advancements, the development of effective cancer screening tools based on serum biomarker measurements has thus far failed to achieve a meaningful clinical impact. The incremental progress observed over the course of serum biomarker development suggests that further refinements based on novel approaches may yet result in a breakthrough. The use of urine as an analytical biofluid for biomarker development may represent such an approach. The unique characteristics of urine including a high level of stability, ease of sampling, and an inactive and low-complexity testing matrix offer several potential advantages over the use of serum. A number of recent reports have demonstrated the utility of urine in the identification of novel cancer biomarkers and also the improved performance of biomarkers previously evaluated in serum. In this review, advancements related to the use of urine biomarkers within the settings of ovarian, breast, and pancreatic cancer are presented and discussed. Findings regarding the identification of specific urine biomarkers for each disease are highlighted along with comparative analyses of urine and serum biomarkers as diagnostic tools.Keywords
This publication has 91 references indexed in Scilit:
- Detection of the HE4 protein in urine as a biomarker for ovarian neoplasmsCancer Letters, 2010
- Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rateKidney International, 2010
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Paradoxical glomerular filtration of carbon nanotubesProceedings of the National Academy of Sciences, 2010
- Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal massGynecologic Oncology, 2010
- Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic CancerGastroenterology, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnosticsProteomics – Clinical Applications, 2008
- Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasiaBritish Journal of Cancer, 2008
- Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentGynecologic Oncology, 2007